Adial Pharmaceuticals reported a net loss of $1.8 million for the third quarter of 2025, compared to a net loss of $2.2 million for the same period in 2024. Research and development expenses decreased by approximately $0.5 million, or 50%, due to lower clinical activity. General and administrative expenses increased by about $0.1 million, or 5%, mainly due to the timing of the company's annual meeting. Cash and cash equivalents were $4.6 million as of September 30, 2025, down from $5.9 million as of June 30, 2025. The company expects its current cash position to fund operations into the second quarter of 2026. Business developments included the filing of an updated provisional patent application for AD04, its lead investigational drug for Alcohol Use Disorder, and progress toward FDA approval.